# Elecoglipron: A Second Oral GLP-1 Pill in Phase 2

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/elecoglipron-oral-glp1-pipeline

> Weight reductions from 2.6% to 10.5% at 26 weeks depending on dose, against 0.6% on placebo. 93% completed the study but only 75% completed the assigned treatment.

## Key points

- Week 26: −2.6% at 5 mg up to −10.5% at 75 mg, against −0.6% placebo.
- 93% completed the study; only 75% completed the assigned treatment.
- Adverse events reported by 84–98% across doses, versus 84% on placebo.
- Phase 2, not purchasable, and as a small molecule not compoundable either.

A second oral GLP-1 pill has reported phase 2 results. Elecoglipron produced weight reductions ranging from 2.6% to **10.5%** at 26 weeks depending on dose, against 0.6% on placebo.[1] Those figures need the completion rate beside them: 93% finished the study, but only **75% finished their assigned treatment**. Completion is where an earlier pill, [danuglipron](https://glpwatchdog.org/research/danuglipron-the-pill-most-people-stopped), came apart: fewer than four in ten finished treatment.

## What was tested

VISTA was a multicenter dose-ranging phase 2 trial in adults with obesity or overweight, funded by AstraZeneca, which develops the drug under the code AZD5004. The tablet is taken once daily without food or fluid restrictions. Participants had a mean age of 48.4 and a mean body weight of 106.9 kg, with a mean BMI of 38.2. Just under three quarters were women.[1]

*Estimated average weight change after 26 weeks, as given in the published report.*

| Arm | Weight change | Reaching ≥5% loss |
| --- | --- | --- |
| Placebo | −0.6% | 15.6% |
| Elecoglipron, lowest dose (5 mg) | −2.6% | — |
| Elecoglipron, highest dose (75 mg, weekly titration) | −10.5% | — |
| Across elecoglipron doses | — | 40.4% to 88.8% |

A dose-ranging study reports a range for a reason: the arms are not equivalent, and the top arm is not the drug’s result but the best of several candidates for what a phase 3 dose might be. Quoting 10.5% alone describes one of five active arms.

## The tolerability question

Adverse events were reported by between 84% and 98% of participants across the elecoglipron doses, against 84% on placebo. The most common were nausea, constipation, diarrhea, headache and vomiting, the familiar pattern for this class.[1]

> Ninety-three percent stayed in the study. Seventy-five percent stayed on the drug. The gap between those numbers is the finding.

A quarter of participants coming off their assigned treatment inside 26 weeks is a real signal, and it is the kind of detail that disappears from summaries. It does not mean the drug will fail. Dose-ranging studies deliberately include doses that turn out to be too high, and finding the ceiling is part of the point. It does mean the eventual phase 3 dose is likely to sit below the one that produced 10.5%.

## Why an oral small molecule matters

Semaglutide and tirzepatide are peptides, which is why they are injected and why the oral version of semaglutide needs an absorption carrier and a strict empty-stomach routine. It is also why other tablets taken alongside it cut its absorption by a third, as we covered in [interactions](https://glpwatchdog.org/research/glp1-and-your-other-medications).

A small molecule avoids all of that. It can be manufactured at scale in a way peptides cannot, which bears directly on the shortages this register has tracked from the commercial end. The first of these to reach approval was orforglipron, covered in [our Foundayo article](https://glpwatchdog.org/research/foundayo-orforglipron-oral-glp1); elecoglipron is a second, from AstraZeneca, still two phases behind it.

> **Nobody can buy this.** It is a phase 2 result supporting phase 3 investigation, which is years from a pharmacy even if everything goes well. And because it is not an approved drug or a component of one, a compounding pharmacy has no lawful way to supply it either (see [what cannot legally be compounded](https://glpwatchdog.org/research/what-cannot-legally-be-compounded)). Anything sold under this name today is not what it claims to be.

## Frequently asked questions

### What is elecoglipron?

An oral small-molecule GLP-1 receptor agonist from AstraZeneca, taken once daily, in development after a phase 2 trial. In a 26-week dose-ranging trial it produced weight reductions from 2.6% at the lowest dose to 10.5% at the highest, against 0.6% on placebo.

### How well tolerated was it?

Less well than the headline suggests. Adverse events were reported by 84% to 98% of participants across doses against 84% on placebo, and while 93% completed the study only 75% completed their assigned treatment. A quarter came off the drug within 26 weeks.

### Is 10.5% the result?

It is the best arm of a dose-ranging study, not the drug's result. These trials deliberately test doses that may prove too high, and the tolerability data suggest a phase 3 dose is likely to sit below the one that produced 10.5%.

### Why do oral small molecules matter?

Semaglutide and tirzepatide are peptides, which is why they are injected and why oral semaglutide needs an absorption carrier and strict dosing conditions. Small molecules avoid that and can be manufactured at far greater scale, which bears directly on supply.

### Can I get it, or a compounded version?

Neither. It is a phase 2 result and years from a pharmacy at best, and because it is not an approved drug, no compounding pharmacy can lawfully supply it. Anything sold under this name today is not what it claims to be.

## References

1. Davies MJ, Aroda VR, Rosenstock J, et al. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. The Lancet. 2026. PMID: 42259337. https://pubmed.ncbi.nlm.nih.gov/42259337/

---

Cite as: GLP Watchdog, Nora Bissett, "Elecoglipron: A Second Oral GLP-1 Pill in Phase 2", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/elecoglipron-oral-glp1-pipeline

Canonical HTML page: https://glpwatchdog.org/research/elecoglipron-oral-glp1-pipeline

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
